Skip to content

Dimension® Flex® reagent cartridge CRE2 10872079Recalls & reported problems

Siemens Healthcare Diagnostics Inc. · Creatinine Flex® reagent cartridge, 480 tests · Class 2

Data updated Oct 18, 2026 from official FDA records · Editorial policy

1 open recall names this device. See the recall details and contact the manufacturer or your healthcare provider.

Adverse event reports
9
Deaths reported
0
Injuries reported
0
Recalls naming it
1

Summary

The FDA's MAUDE database contains 9 adverse event reports that list this exact device (DI 00630414595009), received between Oct 21, 2021 and Apr 7, 2026 — classified as 9 malfunctions.

The most frequently reported specific device problem is “Low Test Results” (8 reports).

1 FDA recall record name this device's identifier, 1 still open.

Reports come from manufacturers, hospitals and patients and are not verified by the FDA. A report does not prove the device caused the event, and counts can't be used to compare devices or estimate failure rates. What reports can and can't tell you · How this data works · Data updated Oct 18, 2026.

Reports received per month

Nov 2023: 0 reportsDec 2023: 0 reportsJan 2024: 0 reportsFeb 2024: 0 reportsMar 2024: 0 reportsApr 2024: 0 reportsMay 2024: 0 reportsJun 2024: 0 reportsJul 2024: 1 reportsAug 2024: 0 reportsSep 2024: 0 reportsOct 2024: 0 reportsNov 2024: 0 reportsDec 2024: 0 reportsJan 2025: 0 reportsFeb 2025: 0 reportsMar 2025: 0 reportsApr 2025: 0 reportsMay 2025: 0 reportsJun 2025: 0 reportsJul 2025: 0 reportsAug 2025: 0 reportsSep 2025: 0 reportsOct 2025: 0 reportsNov 2025: 0 reportsDec 2025: 0 reportsJan 2026: 0 reportsFeb 2026: 0 reportsMar 2026: 2 reportsApr 2026: 5 reportsMay 2026: 0 reportsJun 2026: 0 reportsJul 2026: 0 reportsAug 2026: 0 reportsSep 2026: 0 reportsOct 2026: 0 reports2024202520265
Last 36 months. The most recent month may be incomplete.

Recalls naming this device

  1. Mar 18, 2026Class IIOpen, Classified

    Siemens Healthcare Diagnostics is recalling certain lots of Dimension Creatinine Flex reagent cartridge (Dimension CRE2) because a potential imprecision in the Dimension CRE2 quality control (QC) and patient sample results using lot numbers GA6307 and BA7005 on the Dimension System. This imprecision may lead to erroneously decreased or increased creatinine patient results

    Z-1980-2026 · Root cause: Under Investigation by firm · Recall details · FDA record ↗

Most reported problems

Device problems

  • Low Test Results8
  • High Test Results1

Patient problems

  • No Clinical Signs, Symptoms or Conditions9

Recent adverse event reports

The 9 most recent of 9 reports, in the reporter's own words as published by the FDA.

  • MalfunctionApr 7, 2026Low Test Results

    THE CUSTOMER REPORTED THAT THE ERRONEOUSLY DEPRESSED CREATININE (CRE2) RESULTS WERE OBTAINED ON FOUR PATIENT SAMPLES ON THE DIMENSION EXL WITH LM INTEGRATED CHEMISTRY SYSTEM. THE INITIAL RESULTS WERE REPORTED TO THE PHYSICIAN(S) AND WERE NOT QUESTIONED. THE SAME SAMPLES WERE REPEATED ON THE ORIGINAL SYSTEM AND OBTAINED HIGHER RESULTS. THE REPEAT RESULTS OBTAINED WERE CONSIDERED CORRECT AND REPORTED TO THE PHYSICIAN(S). THERE ARE NO KNOWN REPORTS OF PATIENT INTERVENTION OR ADVERSE HEALTH CONSEQUENCES DUE TO THE ERRONEOUSLY DEPRESSED CREATININE (CRE2) RESULTS.

    Patient problems: No Clinical Signs, Symptoms or Conditions

    MAUDE report 24797148 ↗
  • MalfunctionApr 7, 2026Low Test Results

    THE CUSTOMER REPORTED THAT AN ERRONEOUSLY DEPRESSED CREATININE (CRE2) RESULT WAS OBTAINED ON A PATIENT SAMPLE ON THE DIMENSION EXL WITH LM INTEGRATED CHEMISTRY SYSTEM. THE INITIAL RESULT WAS REPORTED TO THE PHYSICIAN(S) AND WAS NOT QUESTIONED. THE SAME SAMPLE WAS REPEATED ON THE ORIGINAL SYSTEM AND OBTAINED A HIGHER RESULT. THE REPEAT RESULT OBTAINED WAS CONSIDERED CORRECT AND REPORTED TO THE PHYSICIAN(S). THERE ARE NO KNOWN REPORTS OF PATIENT INTERVENTION OR ADVERSE HEALTH CONSEQUENCES DUE TO AN ERRONEOUSLY DEPRESSED CREATININE (CRE2) RESULT.

    Patient problems: No Clinical Signs, Symptoms or Conditions

    MAUDE report 24797147 ↗
  • MalfunctionApr 7, 2026Low Test Results

    THE CUSTOMER REPORTED THAT THE ERRONEOUSLY DEPRESSED CREATININE (CRE2) RESULTS WERE OBTAINED ON TWO PATIENT SAMPLES ON THE DIMENSION EXL WITH LM INTEGRATED CHEMISTRY SYSTEM. THE INITIAL RESULTS WERE REPORTED TO THE PHYSICIAN(S) AND WERE NOT QUESTIONED. THE SAME SAMPLES WERE REPEATED ON THE ORIGINAL SYSTEM AND OBTAINED HIGHER RESULTS. THE REPEAT RESULTS OBTAINED WERE CONSIDERED CORRECT AND REPORTED TO THE PHYSICIAN(S). THERE ARE NO KNOWN REPORTS OF PATIENT INTERVENTION OR ADVERSE HEALTH CONSEQUENCES DUE TO THE ERRONEOUSLY DEPRESSED CREATININE (CRE2) RESULTS.

    Patient problems: No Clinical Signs, Symptoms or Conditions

    MAUDE report 24797144 ↗
  • MalfunctionApr 7, 2026Low Test Results

    THE CUSTOMER REPORTED THAT THE ERRONEOUSLY DEPRESSED CREATININE (CRE2) RESULTS WERE OBTAINED ON FOUR PATIENT SAMPLES ON THE DIMENSION EXL WITH LM INTEGRATED CHEMISTRY SYSTEM. THE INITIAL RESULTS WERE REPORTED TO THE PHYSICIAN(S) AND WERE NOT QUESTIONED. THE SAME SAMPLES WERE REPEATED ON THE ORIGINAL SYSTEM AND OBTAINED HIGHER RESULTS. THE REPEAT RESULTS OBTAINED WERE CONSIDERED CORRECT AND REPORTED TO THE PHYSICIAN(S). THERE ARE NO KNOWN REPORTS OF PATIENT INTERVENTION OR ADVERSE HEALTH CONSEQUENCES DUE TO THE ERRONEOUSLY DEPRESSED CREATININE (CRE2) RESULTS.

    Patient problems: No Clinical Signs, Symptoms or Conditions

    MAUDE report 24797143 ↗
  • MalfunctionApr 7, 2026Low Test Results

    THE CUSTOMER REPORTED THAT THE ERRONEOUSLY DEPRESSED CREATININE (CRE2) RESULTS WERE OBTAINED ON TEN PATIENT SAMPLES ON THE DIMENSION EXL WITH LM INTEGRATED CHEMISTRY SYSTEM. THE INITIAL RESULTS WERE REPORTED TO THE PHYSICIAN(S) AND WERE NOT QUESTIONED. THE SAME SAMPLES WERE REPEATED ON THE ORIGINAL SYSTEM AND OBTAINED HIGHER RESULTS. THE REPEAT RESULTS WERE CONSIDERED CORRECT AND REPORTED TO THE PHYSICIAN(S). THERE ARE NO KNOWN REPORTS OF PATIENT INTERVENTION OR ADVERSE HEALTH CONSEQUENCES DUE TO ERRONEOUSLY DEPRESSED CREATININE (CRE2) RESULTS.

    Patient problems: No Clinical Signs, Symptoms or Conditions

    MAUDE report 24797135 ↗
  • MalfunctionMar 31, 2026Low Test Results

    THE CUSTOMER REPORTED THAT AN ERRONEOUSLY DEPRESSED CREATININE (CRE2) RESULT WAS OBTAINED ON A PATIENT SAMPLE ON A DIMENSION EXL 200 INTEGRATED CHEMISTRY SYSTEM. THE ERRONEOUS RESULT WAS REPORTED TO THE PHYSICIAN(S), WHO QUESTIONED THE RESULT. THE SAMPLE WAS REPROCESSED ON A NON-SIEMENS SYSTEM. THE REPROCESSED RESULT WAS HIGHER THAN THE ERRONEOUS RESULT AND WAS CONSIDERED CORRECT. A CORRECTED REPORT WAS ISSUED BY REPORTING THE REPROCESSED RESULT TO THE PHYSICIAN(S). THERE ARE NO KNOWN REPORTS OF PATIENT INTERVENTION OR ADVERSE HEALTH CONSEQUENCES DUE TO THE ERRONEOUSLY DEPRESSED CREATININE (CRE2) RESULT.

    Patient problems: No Clinical Signs, Symptoms or Conditions

    MAUDE report 24743756 ↗
  • MalfunctionMar 11, 2026Low Test Results

    THE CUSTOMER REPORTED TO SIEMENS A POTENTIALLY ERRONEOUSLY DEPRESSED CREATININE (CRE2) RESULT ON ONE (1) PATIENT SAMPLE WAS OBTAINED DURING A COMPARISON STUDY ON A DIMENSION EXL 200 INTEGRATED CHEMISTRY SYSTEM. THE POTENTIALLY ERRONEOUSLY DEPRESSED RESULT WAS REPORTED TO THE PHYSICIAN AND NOT QUESTIONED. THE SAME SAMPLE WAS REPROCESSED FOR TROUBLESHOOTING PURPOSES USING A DIFFERENT LOT OF CREATININE (CRE2) ON THE ORIGINAL DIMENSION EXL 200 INTEGRATED CHEMISTRY SYSTEM AND OBTAINED A HIGHER RESULT, WHICH WAS NOT REPORTED TO THE PHYSICIAN. THE CUSTOMER PERFORMED THE COMPARISON STUDY FOR TROUBLESHOOTING PURPOSES AND IS NOT ALLEGING ANY OF THE RESULTS TO BE DISCORDANT. IT IS UNKNOWN WHICH RESULT IS CONSIDERED CORRECT. THERE ARE NO KNOWN REPORTS OF PATIENT INTERVENTION OR ADVERSE HEALTH CONSEQUENCES DUE TO THE POTENTIALLY ERRONEOUSLY DEPRESSED CRE2 RESULT.

    Patient problems: No Clinical Signs, Symptoms or Conditions

    MAUDE report 24576050 ↗
  • MalfunctionJul 17, 2024Low Test Results; Low Test Results

    THE CUSTOMER REPORTED TO SIEMENS THAT THEY OBTAINED AN ERRONEOUSLY DEPRESSED CREATININE (CRE2) RESULT WITH A DELTA CHECK FLAG ON A PATIENT SAMPLE ON A DIMENSION EXL WITH LM SYSTEM. THE ERRONEOUSLY DEPRESSED RESULT WAS REPORTED TO THE PHYSICIAN(S), AND THE RESULT WAS QUESTIONED. THE SAME SAMPLE WAS REPROCESSED ON THE ORIGINAL DIMENSION EXL WITH LM SYSTEM AND ON AN ALTERNATE DIMENSION EXL WITH LM SYSTEM. HIGHER REPROCESSED RESULTS WERE OBTAINED AND CONSIDERED CORRECT. A CORRECTED REPORT WAS ISSUED. THERE ARE NO KNOWN REPORTS OF PATIENT INTERVENTION OR ADVERSE HEALTH CONSEQUENCES DUE TO THE ERRONEOUSLY DEPRESSED CREATININE (CRE2) RESULT.

    Patient problems: No Clinical Signs, Symptoms or Conditions

    MAUDE report 19760642 ↗
  • MalfunctionOct 21, 2021High Test Results; High Test Results

    AN ELEVATED CREATININE (CRE2) PATIENT SAMPLE RESULT WAS OBTAINED ON TWO DIMENSION® EXL¿ 200 INTEGRATED CHEMISTRY SYSTEMS WHEN COMPARED TO A CREATININE RESULT ON THE SAME SAMPLE PROCESSED WITH AN ALTERNATE METHODOLOGY ON AN ALTERNATE SIEMENS SYSTEM. THE RESULTS FROM BOTH SYSTEMS WERE REPORTED TO THE PHYSICIAN(S) WHO QUESTIONED THE DIFFERENCE IN RESULTS. THE CUSTOMER DOES NOT CONSIDER ANY OF THE RESULTS TO BE DISCORDANT. NO CORRECTED REPORTS WERE ISSUED. THE PATIENT WAS ADMITTED TO THE FACILITY BASED ON THE CRE2 RESULTS FROM THE DIMENSION EXL SYSTEMS. THERE ARE NO KNOWN REPORTS OF PATIENT INTERVENTION, UNNECESSARY TREATMENT OR ADVERSE HEALTH CONSEQUENCES DUE TO THE CRE2 RESULTS FROM THE DIMENSION EXL SYSTEMS OR THE ADMISSION TO THE HOSPITAL.

    Patient problems: No Clinical Signs, Symptoms or Conditions

    MAUDE report 12672346 ↗

Other ALKALINE PICRATE, COLORIMETRY, CREATININE devices

All ALKALINE PICRATE, COLORIMETRY, CREATININE devices →

Sources and updates

How reports and recalls are matched · Editorial policy · Report an error on this page